Skip to Main Content

A team of biotech veterans say they have raised $3 billion to create a continent-spanning company that will aim to battle disease by reprogramming the fundamental machinery of living cells.

It appears to be the largest venture capital fundraising effort in biotech history, based on a survey of data from Pitchbook.


The company, Altos Labs, is the brainchild of Richard Klausner, a serial biotech entrepreneur who has previously founded two biotechnology companies that raised large sums of money and were sold to larger firms. Klausner is being joined by Hans Bishop, who served as CEO of those companies, Juno Biotechnology and Grail. And Hal Barron, the chief scientific officer of GlaxoSmithKline, will join as the new company’s CEO in August.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.